Gene Therapy for Male Erectile Dysfunction - 15/08/11
Abstract |
The potential clinical advantages of a gene transfer therapy–based approach to treatment of genitourinary smooth muscle–based disorders are several: potential single therapy for restoration of normal bladder or erectile function; eliminating the need for daily medication; use in combination with other therapies to reduce dose requirements and side effects; and development of mechanism-based, patient-specific treatment approaches. With the safe administration of hMax-K to men with erectile dysfunction in the first human phase 1 trial and the initiation of the phase 1 trial of hMaxi-K for patients who have detrusor overactivity, we have entered an exciting new era in the development of safe enduring therapies for genitourinary disorders.
Le texte complet de cet article est disponible en PDF.Plan
| Portions of this text were published previously in Melman A, Bar-Chama N, McCullough A, et al. hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum Gene Ther 2006;18:1165–76; with permission. |
Vol 34 - N° 4
P. 619-630 - novembre 2007 Retour au numéro
Article précédent
- Penile Rehabilitation Following Radical Prostatectomy: Role of Early Intervention and Chronic Therapy
- Craig D. Zippe, Geetu Pahlajani
- Priapism: Current Principles and Practice
- Arthur L. Burnett, Trinity J. Bivalacqua
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?